Aug 4, 2025
Lisa Mcclain- Amount
- $1,001 to $15,000
- Filed
- Sep 12, 2025
Congress ticker disclosure profile
As of August 4 at 9:02 AM EDT
Public STOCK Act rows mentioning
A factual page for public Congressional disclosures that reference DBX. Veridion shows filed rows, disclosed amount ranges, dates, and source links. It does not imply motive or wrongdoing.
90d rows
0
Feed lifetime
11
Member filers
6
Disclosed ranges
$415K
Most active member desks
6 buys vs 5 sells
Latest trade Aug 4, 2025
Aug 4, 2025
Lisa McclainJul 22, 2025
Lisa McclainApr 22, 2025
Julia LetlowJan 13, 2025
Rob BresnahanOct 23, 2024
Julia LetlowJun 2, 2022
Ro KhannaMay 23, 2022
Ro KhannaFeb 17, 2022
Ro KhannaNov 16, 2020
Peter WelchJul 3, 2019
Peter WelchMar 27, 2018
Nancy Pelosi| Date | Member | Action | Amount | Filed | Receipt |
|---|---|---|---|---|---|
| Aug 4, 2025 | Lisa Mcclain | Sell | $1,001 to $15,000 | Sep 12, 2025 | Open card |
| Jul 22, 2025 | Lisa Mcclain | Buy | $1,001 to $15,000 | Aug 13, 2025 | Open card |
| Apr 22, 2025 | Julia Letlow | Sell | $1,001 to $15,000 | Jan 13, 2026 | Open card |
| Jan 13, 2025 | Rob Bresnahan | Sell | $1,001 to $15,000 | Feb 13, 2025 | Open card |
| Oct 23, 2024 | Julia Letlow | Buy | $1,001 to $15,000 | Jan 13, 2026 | Open card |
| Jun 2, 2022 | Ro Khanna | Buy | Receipt pending ingestion | Jun 10, 2022 | Open card |
| May 23, 2022 | Ro Khanna | Sell | Receipt pending ingestion | Jun 10, 2022 | Open card |
| Feb 17, 2022 | Ro Khanna | Buy | Receipt pending ingestion | Mar 8, 2022 | Open card |
| Nov 16, 2020 | Peter Welch | Sell | Receipt pending ingestion | Dec 4, 2020 | Receipt pending ingestion |
| Jul 3, 2019 | Peter Welch | Buy | Receipt pending ingestion | Jul 31, 2019 | Receipt pending ingestion |
| Mar 27, 2018 | Nancy Pelosi | Buy | $250,001 to $500,000 | Apr 16, 2018 | Open card |
Source creed
This page is assembled from public STOCK Act disclosure records in the Veridion warehouse. 6 of 11 filed rows include disclosed amount ranges (55%). Rows without ranges stay labeled. Identification only; it does not imply motive or wrongdoing.
Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.